TP53 and cancer: p53 mutation therefore shows promise as a biomarker in Barrett's patients (Gleeson et al, 1998; Reid, 2001), but its use as an early biomarker for risk of cancer development relies on its detection as early as possible in premalignant Barrett's tissues.